Anti-HER2 CAR T-cell therapy (Seattle Children's Hospital)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-HER2 CAR T-cell therapy (Seattle Children's Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsT lymphocyte replacements
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsCentral Nervous System Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSeattle Children'S Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesSeattle Children'S Research Institute
Inactive CompaniesN/A
Active IndicationsCentral Nervous System Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A